1. Home
  2. Category
  3. Symptoms/Side Effects

Hypersensitivity Reaction

NCPD Article

Oxaliplatin: Detection and Management of Hypersensitivity Reactions

Barbara B. Rogers
Terri Cuddahy
Caralyn Briscella
Nicole Ross
Anthony J. Olszanski
Crystal S. Denlinger
CJON 2019, 23(1), 68-75 DOI: 10.1188/19.CJON.68-75
Background: Oxaliplatin is used extensively for the treatment of gastrointestinal cancer and other malignancies, with increased frequency of use in recent years. Hypersensitivity reactions (HSRs) can pose a major problem in clinical practice because they can limit the use of oxaliplatin in the care...
5
Average: 5 (2 votes)
Read this Article
Article

Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment

Carissa Laudati
Caroline Clark
Andrea Knezevic
Zhigang Zhang
Margaret Barton-Burke
CJON 2018, 22(4), 407-414 DOI: 10.1188/18.CJON.407-414
Background: Strategies to reduce hypersensitivity reaction (HSR) incidence with rituximab include premedications and slow titration. Literature is lacking on the priming method used when preparing rituximab IV lines and the potential impact on HSR incidence. Objectives: The primary objective is to...
4.333335
Average: 4.3 (6 votes)
Read this Article
Online Exclusive Article

Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia

Van Thu Huynh
Sharon Bergeron
CJON 2017, 21(5), E248-E259 DOI: 10.1188/17.CJON.E248-E259
Background: Acute lymphoblastic leukemia (ALL) is a common cancer in children, and outcomes have greatly improved because of the refinement of multiagent chemotherapy regimens that include intensified asparaginase therapy. Asparaginase, a cornerstone of modern pediatric chemotherapy regimens for...
5
Average: 5 (3 votes)
Read this Article
Article

Self-Administered Premedication: Improving Taxane Chemotherapy Treatment

Kristin Roper
Mary Lou Siefert
Frances Fuller
Diane Lucier
Donna L. Berry
CJON 2017, 21(2), 234-239 DOI: 10.1188/17.CJON.234-239
Background: Patients receiving taxane therapy are at risk for hypersensitivity reactions without appropriate premedication management. Patients must understand the importance of taking premedications as prescribed to prevent reactions. Objectives: The objectives of this study were to implement and...
4
Average: 4 (2 votes)
Read this Article
Oncology Essentials

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens

Wendy Pritchett
Karen Kinsley
CJON 2016, 20(5), 555-556 DOI: 10.1188/16.CJON.555-556
Fosaprepitant dimeglumine (Emend IV®) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regimens. Aprepitant (Emend®) is an oral medication that is administered for three consecutive days, whereas fosaprepitant is a single-dose IV medication that is administered on...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.